Ravishankar K, Tayade Himanshu, Mandlik Rahul
'The Headache and Migraine Clinic', Jaslok Hospital and Research Centre, 15, G. Deshmukh Marg, Mumbai 400026, India.
J Assoc Physicians India. 2011 Aug;59:494-7.
The aim of the present study was to compare the analgesic efficacy of a single dose of sublingual piroxicam to that of a placebo during acute attacks of migraine without aura.
The drug (N = 30) or a placebo (N = 30) was administered, on randomisation and double-blind basis, to 60 patients between 18 and 50 years of age suffering from migraine without aura. The patients were instructed to take a single tablet sublingually [corresponding to piroxicam 40 mg or placebo] and the severity of the painful symptomatology and associated symptoms were evaluated by this study.
The patients treated with sublingual piroxicam showed a significant (P < 0.05) decrease in pain intensity 15 minutes after ingestion; they went on to show a further reduction in the 24 hours after drug administration. On the contrary, the group treated with placebo showed a significant reduction of symptoms only after seven hours of observation. Associated symptoms disappeared significantly (P < 0.05) after sublingual piroxicam administration. In 83.3%, the drug resulted in excellent to good response as compared to only 10% in the placebo group. No local and systemic side effects were reported with sublingual piroxicam.
The present study has demonstrated that for the acute management of migraine without aura sublingual piroxicam showed significant analgesic effect with excellent tolerability.
本研究旨在比较单剂量舌下含服吡罗昔康与安慰剂对无先兆偏头痛急性发作的镇痛效果。
将60例年龄在18至50岁之间的无先兆偏头痛患者随机、双盲分为两组，分别给予药物（n = 30）或安慰剂（n = 30）。患者被要求舌下含服一片药（相当于吡罗昔康40mg或安慰剂），本研究评估疼痛症状及相关症状的严重程度。
舌下含服吡罗昔康的患者在服药15分钟后疼痛强度显著降低（P < 0.05）；在给药后的24小时内疼痛进一步减轻。相反，安慰剂组仅在观察7小时后症状才有显著减轻。舌下含服吡罗昔康后相关症状显著消失（P < 0.05）。与安慰剂组仅10%的良好反应率相比，83.3%的患者使用该药后反应良好至极佳。未报告舌下含服吡罗昔康有局部和全身副作用。
本研究表明，对于无先兆偏头痛的急性治疗，舌下含服吡罗昔康显示出显著的镇痛效果且耐受性良好。
